



**Supplementary Fig.1** : Immunohistochemistry (IHC) of ER, PR, Ki67 and P53.

Notes: (A) Negative expression of ER; (B) Positive expression of ER; (C) Negative expression of PR; (D) Positive expression of PR; (E) Negative expression of P53; (F) Positive expression of P53; (G) Low expression of Ki67; (H) High expression of Ki67. Scale bar: 200  $\mu\text{m}$ .



**Supplementary Fig.2:** Flow chart for patient inclusion



**Supplementary Fig.3:** Distribution of patients according to the Ki67 labeling index

Notes: Ki67 labeling index ranged from 0 to 90% (median 30%)

**Supplementary Tab. 1 Basline characteristics of relapsed patients (n=46).**

<b>Characteristics</b>	<b>All patients(n=46)</b>	<b>%</b>
<b>Sites of relapsed</b>		
Vaginal stump	2	4.3
Central pelvic region	13	28.3
Lymph nodes (upper para-aortic)	5	10.9
Peritoneal metastases	9	19.6
Metastasis to other organs	17	37.0
<b>Recurrence-free survival (months)</b>		
Median	22.50	
Mean ( $\pm$ SD)	23.37( $\pm$ 10.96)	
Range	6-48	
<b>Follow-up (months)</b>		
Median	36	
Mean ( $\pm$ SD)	36.74( $\pm$ 13.33)	
Range	12-60	

**Supplementary Tab. 2 Comparison of recurrence-free survival of patients with early low-risk endometrial cancer who didn't receive adjuvant treatment after surgery between low-Ki67 and high-Ki67 group(n=118)**

Groups	All patients (n=118)	Recurrence patients (n=8)	3-year recurrence-free survival (95%CI)	P-value
Low-Ki67 group	91 (77.1%)	1	98.7% (96.2%-100%)	0.000
High-Ki67 group	27 (22.9%)	7	72.6% (55.2%-90.0%)	